A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1 Clinical Trial

Official title:
A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Status Terminated

Clinical Trial Summary

A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1 administered via-intravenous infusion (IV)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02795325
Study type	Interventional
Source	Dicerna Pharmaceuticals, Inc.
Contact
Status	Terminated
Phase	Phase 1
Start date	May 13, 2016
Completion date	October 14, 2016

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT02830009` - IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA	N/A
Completed	`NCT03067142` - Proteomics of Primary Hyperoxaluria Type 1
Active, not recruiting	`NCT04152200` - A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1	Phase 3
Recruiting	`NCT05001269` - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function	Phase 2
Recruiting	`NCT04982393` - BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Recruiting	`NCT04580420` - Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD	Phase 2